Psoriasis Drugs Market By Production, Sales, Supply, Demand, Analysis and Forecast to 2020-2027

(Global QYResearch via Comtex)

The global psoriasis drugs market is forecast to reach USD 39.00 Billion by 2027, according to a new report by Acumen research and Consulting. Psoriasis can be defined as a skin condition, which accelerates the life cycle of skin cells. It results in cells to develop on the surface. It is usually considered to be a chronic condition. The condition has an unpredictable course of symptoms, significant comorbidities, and various external triggers impacting the condition that includes metabolic syndrome, arthritis, and cardiovascular diseases, among others. The immune system is considered to play an integral role in the condition. The condition also affects nails apart from skin. When a particular area on the skin is affected by the disease, the skin lesion is usually localized, which are sharply demarcated by plaques and red papules that are covered by silver or white scales. These lesions are generally symmetrical and cause stinging, itching, and pain. Herein the main aim of the treatment is to prevent the skin cells from growing quickly. There is no cure to the disease; however, these drugs help in managing the symptoms.

In context to region, Europe can be seen to occupy a prominent market share. The market share held by the region is attributed to continuously developing healthcare sector, rising focus on management of not just the condition but comorbidities as well, which are supporting the market growth in this region.

Download sample copy of [email protected]

Further key findings from the report suggest

  • The Psoriasis Drugs market held a market share of USD 16.21 Billion in the year 2018 that is forecasted to grow at a rate of 9.6% during the forecast period.
  • In context to Treatment Type, the Biologics segment generated the highest revenue of USD 6.32 Billion in the year 2020, with a growth rate of 9.9% during the forecast period. The ability of these drugs to treat the condition by targeting particular areas of the immune system thereby treating the condition form the base, results in its high acceptance among care providers that contributes to the revenue generated by this segment.
  • In context to Therapeutic Class, the Interleukin Inhibitors segment is projected to witness the fastest growth rate of 10.3% during the forecast period, which is expected to occupy 27.5% of the market by 2027. The growth rate witnessed by the segment is attributed to the significant role it plays in the pathogenesis of plaque psoriasis, one of the most common form of psoriasis, which results in its elevated demand among care providers.
  • In context to distribution channel, it is mentionable here that the E-commerce segment is projected to witness the fastest growth rate of 11.6% during the forecast period, which is expected to generate USD 7.80 Billion by 2027. The growth rate witnessed by the segment is resultant of continuous growth in the online medicine store and associated upsurge in online medicine shopping culture.
  • In context to Application, the Plaque Psoriasis segment held the largest market share of 53.0% in 2020, with a CAGR of 9.7% during the forecast period. The high occurrence rate of the condition and associated increased demand for drugs and medications for treating the disease contributes to the market share occupied by this segment.
  • In regards to the region, Asia Pacific is projected to witness the fastest growth rate of 10.3% during the forecast, which is expected to hold 4% of the market by 2027. The growth rate witnessed by the region is resultant of rising awareness about the importance of early diagnosis of the condition and unmet healthcare needs of care users that are opening new avenues for the market in this region.
  • Some of the major players involved in the supply of psoriasis drugs market include Johnson & Johnson, Novartis International AG, Pfizer Inc, Merck and Co. Inc, Celgene Corporation, Janssen Biotech Inc, Stiefel Laboratories Inc, Takeda Pharmaceutical Company Limited, Amgen Inc., and AbbVie among others.

Segments covered in the report:

The market can be bifurcated on the basis of therapeutic class, drugs, and geography.

Drugs Outlook (Revenue, USD Billion; 2020-2027)

  • Topicals

Over-the-counter (OTC) topicals

Topical non-steroids

Topical steroids

  • Systemic




  • Biologics

Tumor Necrosis Factor (TNF) Inhibitors

Interleukin 12 and 23 (IL-12/23) Inhibitors

Interleukin 17 (IL-17) Inhibitors

T-cell Inhibitors

Therapeutic Class Outlook (Revenue, USD Billion; 2020-2027)

  • Tumor Necrosis Factor Inhibitor




  • Interleukin Inhibitors





  • Vitamin-D Analogues





Regional Outlook (Revenue in USD Million; 2020-2027)

North America

  • U.S.
  • Canada
  • Mexico


  • UK
  • France
  • Germany
  • Rest of Europe


  • China
  • Japan
  • India
  • Australia
  • Rest of Asia-Pacific

Latin America

  • Brazil
  • Chile
  • Rest of LATAM

Middle East and Africa (MEA)

  • South Africa
  • Saudi Arabia
  • Rest of MEA

Download full study report, click [email protected]

About ARC:

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.

Email: [email protected] | +1 407 915 4157

The post Psoriasis Drugs Market By Production, Sales, Supply, Demand, Analysis and Forecast to 2020-2027 appeared first on Pharma News Desk.

comtex tracking